Cannabinoid-related therapy has been a peak research topic for several decades now, and with the legalization of recreational use in many states, the push for it is lacking proper research at this time. This is mainly due to the classification of a Schedule 1 substance for cannabis, which halts and delays research progress for the majority of states. Not to mention, the limitations of legal use from state to state across the United States.
In short, since it has the potential of being highly abusable, therapeutical cannabinoid-related treatment— that is limited to particular parts of the United States— has been difficult to regulate effectively.
How is Cannabinoid-Related Therapy Being Used Today?
Medicinal use with chronic pain or cancer treatment is the most commonly associated use currently, as well as epilepsy and Huntington's disease. Lacking studies currently are the main reason therapy treatment is being held back currently, but that is looking to be changed in the near future. The regulations of therapy in state legislation varies, and since cannabis is only legal in a portion of the United States, there is room for more of a gray area than a black and white answer at this time.
How will individuals who grow cannabis on their own influence this push for cannabinoid therapy?
Again, state regulations will play a major role in this, as therapy mandates would then have to be reconsidered based on what treatment a patient may be needing attention in. This falls into another gray area that would have to be addressed on some kind of “rolling” scale, where modifications or acceptions would need to be made when fit.
What effect can age have on the use of cannabis in treatment?
Recreational use of cannabis is already recommended to be avoided when taking other medications for older patients. This is to ensure the health and safety of the user long term, which can be detrimental to how cannabinoid therapy is then applied in cases for older patients.
How does cannabinoid-related therapy affect cannabis manufacturing?
Manufacturing could become an even more heavily utilized resource on a professional scale, given that therapy would become a route for many patients to seek help from a professional and be prescribed cannabinoid aid. Depending on the regulation of treatment options for each individual and whether private practices would be licensed to distribute or prescribe would again be a major determining factor on how manufacturing would be affected, yet it’s assumed that providers would become more necessary than ever.